JPS62167725A - 卒中治療剤 - Google Patents

卒中治療剤

Info

Publication number
JPS62167725A
JPS62167725A JP62001981A JP198187A JPS62167725A JP S62167725 A JPS62167725 A JP S62167725A JP 62001981 A JP62001981 A JP 62001981A JP 198187 A JP198187 A JP 198187A JP S62167725 A JPS62167725 A JP S62167725A
Authority
JP
Japan
Prior art keywords
verapamil
stroke
rats
diltiazem
nifedipine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62001981A
Other languages
English (en)
Japanese (ja)
Inventor
フランク・ダブリユー・マークークス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JPS62167725A publication Critical patent/JPS62167725A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
JP62001981A 1986-01-10 1987-01-09 卒中治療剤 Pending JPS62167725A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US818505 1986-01-10
US06/818,505 US4654372A (en) 1986-01-10 1986-01-10 Method for using verapamil for treating stroke

Publications (1)

Publication Number Publication Date
JPS62167725A true JPS62167725A (ja) 1987-07-24

Family

ID=25225695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62001981A Pending JPS62167725A (ja) 1986-01-10 1987-01-09 卒中治療剤

Country Status (8)

Country Link
US (1) US4654372A (enExample)
EP (1) EP0229644B1 (enExample)
JP (1) JPS62167725A (enExample)
AT (1) ATE81006T1 (enExample)
CA (1) CA1284950C (enExample)
DE (1) DE3781904T2 (enExample)
ES (1) ES2046178T3 (enExample)
GR (1) GR3005998T3 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871731A (en) * 1987-10-07 1989-10-03 Marion Laboratories, Inc. Captopril and diltiazem composition and the like
DE3737741A1 (de) * 1987-11-06 1989-05-18 Goedecke Ag Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid
DK0429676T3 (enExample) * 1989-06-16 1997-03-10 Santen Pharmaceutical Co Ltd
RU1804845C (ru) * 1991-02-15 1993-03-30 Институт Органического Синтеза Латвийской Ан Ноотропное вещество
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
KR20040078140A (ko) * 1998-07-10 2004-09-08 노파르티스 아게 발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제
US20100041691A1 (en) * 2006-09-12 2010-02-18 Neurosearch A/S Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein
WO2020157122A1 (en) * 2019-01-29 2020-08-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
IL297333B2 (en) * 2020-04-17 2025-09-01 Honeybrains Llc Preparations and methods for treating neuropsychiatric disorders
WO2026002967A1 (en) 2024-06-24 2026-01-02 Universität Linz Leoligin and derivatives thereof as calcium channel blockers for the prevention and/or treatment of related diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60130517A (ja) * 1983-12-16 1985-07-12 Mitsui Pharmaceut Inc アレルギ−性鼻炎治療剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568677A (en) * 1983-07-23 1986-02-04 Pfizer Inc. 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and antihypertensive agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60130517A (ja) * 1983-12-16 1985-07-12 Mitsui Pharmaceut Inc アレルギ−性鼻炎治療剤

Also Published As

Publication number Publication date
DE3781904T2 (de) 1993-02-25
GR3005998T3 (enExample) 1993-06-07
ES2046178T3 (es) 1995-04-01
US4654372A (en) 1987-03-31
EP0229644A3 (en) 1989-11-23
CA1284950C (en) 1991-06-18
DE3781904D1 (de) 1992-11-05
EP0229644B1 (en) 1992-09-30
ATE81006T1 (de) 1992-10-15
EP0229644A2 (en) 1987-07-22

Similar Documents

Publication Publication Date Title
TW449473B (en) Compositions for inhibition of the pathophysiologic actions in mammals of tumor necrosis factor-alpha
CA2761156C (en) Methods of preventing ischemic injury using peripheral nociceptive stimulation
RU2340342C2 (ru) СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
JP2000507544A (ja) 痛みの治療方法
BRPI0618239A2 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusico
WO2006096434A2 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
JP2004518653A (ja) 不安障害を治療する方法
ES2210957T3 (es) Composiciones farmaceuticas que contienen norastemizol.
DE69625877T2 (de) Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms
WO2009155777A1 (zh) 法舒地尔化合物的用途、方法及其药物组合物
DE69024053T2 (de) Behandlung zur ermässigung von ödem und muskelschäden.
AU678149B2 (en) 5-HT2 receptor antagonist compositions useful in treating venous conditions
US4618621A (en) Method for treating medical conditions involving cerebral ischemia
DE69635754T9 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
US4654372A (en) Method for using verapamil for treating stroke
JP2004521150A (ja) 尿失禁治療用アリール（またはヘテロアリール）アゾリルカルビノール誘導体
DE60301862T2 (de) Kombinationsbehandlung bei akutem myokardinfarkt
US4719212A (en) Therapeutic agent for memory disturbance
US6239162B1 (en) Method for treating depression
US4696924A (en) Method for using diltiazem for treating stroke
JPH0680009B2 (ja) 抗高血圧組み合わせ医薬
WO2005007191A1 (ja) 医薬組成物
DE60019591T2 (de) Behandlung oder hemmung von koronarimplantat vasospasm
Meyer et al. The novel dihydronaphthyridine Ca2+ channel blocker CI-951 improves CBF, brain pHi, and EEG recovery in focal cerebral ischemia
DE69800906T2 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie